The short answer

Most medical device makers report on primary sales, meaning what they ship into their distributor channel, because that is the number their own system captures cleanly. The problem is that primary sales measure sell-in, not sell-through. When distributors are incentivised on shipments rather than consumption, channel inventory quietly grows faster than real demand (BioSpectrum India). The leak is twofold. Capital gets trapped as unsold stock sitting in the channel, and stockouts hit your fastest-moving SKUs before you ever see them coming. Secondary-sales data, meaning what your distributors actually sell to hospitals, clinics and pharmacies, is where real demand lives. For most device companies that data sits scattered across dozens of distributor reports in incompatible formats. Below we explain what that data reveals once it is consolidated, how the two hidden leaks form, and the pipeline we would build to give you a demand signal you can trust.

Primary, secondary, tertiary: what each sales layer actually shows

The three sales layers are not interchangeable, and confusing them is the root of the problem. A device maker who treats the primary number as demand is, in effect, forecasting off a figure that a distributor's ordering behaviour can inflate at will.

Sales layer What it is Who sees it clearly What it hides
Primary (sell-in) Your dispatches to distributors and stockists The manufacturer, in its own ERP Whether that stock is actually moving or just sitting in a warehouse
Secondary (sell-through) Distributor sales to hospitals, clinics and retail pharmacies The distributor, rarely the manufacturer in usable form The gap between what you shipped and what the channel really consumed
Tertiary (sell-out) Actual consumption or dispensing to the end patient Almost no one, without device-level tracking True end demand, and which SKUs are genuinely winning

Primary sales are the number that looks healthy on a quarterly review. Secondary sales are the number that tells you whether that health is real or borrowed against next quarter.

Why primary sales flatter the picture

A distributor takes a large order at quarter-end to hit a scheme target. Your primary-sales report shows a strong quarter. But if the hospitals and pharmacies downstream did not consume at the same rate, you have not sold anything; you have relocated your inventory to someone else's shelf. Analysts are explicit that device companies should treat sell-out, not sell-in, as the core commercial metric precisely to avoid overstocking the channel this way (Alvarez & Marsal).

The fragmented-report problem

The reason most device makers lack secondary-sales visibility is not unwillingness; it is format chaos. A single stockist in India commonly carries 5 to 15 manufacturers, and larger ones handle 30 to 50 (BioPharm International). Each sends its sales-and-stock statement in its own layout: Tally exports, a bespoke Excel template, a scanned PDF, or nothing until chased. Consolidating these by hand is a monthly grind, and by the time the sheet is finished the data is weeks stale. This is the same "last-mile" visibility gap medtech operators describe once product leaves the warehouse: the ERP tracks the dispatch cleanly and then loses sight of what happens next (ConnectSx).

What the consolidated data reveals

Once secondary-sales reports are normalised into one clean dataset (consistent SKU codes, consistent distributor and geography tags, refreshed weekly), the leaks become specific and addressable:

  • Trapped inventory. Distributors that hold weeks of cover on slow SKUs while your factory keeps shipping more, because primary demand looked strong. That is working capital frozen in the channel.
  • Silent stockouts on winners. SKUs selling through faster than they are replenished, going out of stock at the distributor before you notice. Retail research puts out-of-stock losses at roughly 4 percent of sales on their own, a bigger drag than the cost of a little safety stock (IHL Group).
  • True regional demand. Which territories and distributors are genuinely growing versus which are just absorbing quarter-end pushes, the difference between a real market and a channel-stuffing habit.
  • A demand signal you can forecast on. Forecasting off primary sales inherits every channel distortion. Sell-through is closer to reality, which matters because forecast error on newer device lines commonly runs 44 to 53 percent, versus around 31 percent on established products (RK Logistics).

You can put a rupee figure on this leak.

Our AI Stack Audit x-rays your existing data and quantifies the gap in a fixed two-week engagement. No new tools to buy first.

See how the audit works

What a working secondary-sales pipeline looks like

The mechanics matter less than the discipline, but the shape is consistent across the device makers we have helped. A collection layer gathers each distributor's statement on a fixed cadence, whether that means an emailed Tally export, a shared folder, or a portal upload. A mapping layer translates every distributor's columns into one canonical schema, so a stockist who labels a column "Qty Sold" and another who writes "Units Billed" both land in the same field. A reconciliation layer then lines sell-through up against your own dispatch data, SKU by SKU, and flags the two gaps automatically rather than waiting for someone to spot them in a spreadsheet.

The payoff is not a prettier report; it is speed. When the consolidation runs weekly instead of monthly, a stockout on a fast-moving SKU surfaces while there is still time to expedite a shipment, and trapped inventory shows up before the next production run compounds it. The manual grind that used to eat a week of an analyst's month becomes a pipeline that refreshes on its own.

The cost of not seeing it

When you cannot trust your demand signal, you compensate in the most expensive way available: you over-stock everywhere. Field-inventory operators in medtech report carrying three to five times more inventory than needed to avoid stockouts when visibility is poor (ImplantBase). For a device maker the same dynamic shows up as cash tied up in channel inventory on one side and lost orders on your best products on the other, both invisible on a primary-sales report.

How to get to your number

You do not need a new ERP or a channel-management platform to start. The first step is a reconciliation: pull the last several months of distributor secondary-sales statements, map every layout into one schema, and lay sell-through next to your primary dispatches SKU by SKU and distributor by distributor. The gaps (stock going in faster than it comes out, and winners running dry) are your leak, quantified in rupees and units rather than described in the abstract. That reconciliation is the first thing we build, and it is what turns "our channel data is a mess" into a specific figure you can act on.

Our AI Stack Audit does exactly this: we consolidate your fragmented distributor reports, quantify trapped inventory and stockout exposure, and show you where primary and secondary sales have drifted apart. For how we work with pharma and medical-device companies specifically, see our pharma and healthcare practice page.

Key takeaways

  • Primary sales measure what you ship into the channel; secondary sales measure what the channel actually sells. Only the second reflects real demand.
  • Primary sales flatter the picture because quarter-end pushes and scheme-driven orders relocate inventory without consuming it.
  • Most device makers lack secondary-sales visibility because distributor reports arrive in incompatible formats and go stale before they can be consolidated by hand.
  • The two hidden leaks are trapped inventory on slow SKUs and silent stockouts on fast ones, both invisible until sell-in and sell-through sit side by side.
  • Your real number comes from reconciling your own primary dispatches against consolidated distributor secondary-sales data, not from an industry benchmark.

Frequently asked questions

What is the difference between primary and secondary sales for a medical device company?

Primary sales (sell-in) are your dispatches to distributors and stockists, captured cleanly in your own ERP. Secondary sales (sell-through) are what those distributors then sell to hospitals, clinics and pharmacies. Primary tells you what left your warehouse; secondary tells you whether real demand actually absorbed it.

How do device companies track secondary sales through distributors?

By collecting each distributor's periodic sales-and-stock statement and consolidating it into one dataset with consistent SKU and geography codes. The hard part is not collection but normalisation; statements arrive in different formats, so the practical step is a data pipeline that maps every layout into one schema and refreshes on a set cadence.

How do I consolidate distributor data that comes in different formats?

Define one target schema (SKU, distributor, territory, period, quantity, value) and build a mapping for each distributor's export into that schema, so a Tally file, an Excel template and a PDF statement all land in the same clean table. Automating that mapping is what removes the monthly manual grind and keeps the data fresh enough to act on.

How does secondary-sales data help avoid stockouts?

It shows real consumption at the distributor level, so you can see which SKUs are selling through faster than they are being replenished before they run dry. Forecasting off sell-through instead of sell-in removes the channel distortion that makes primary-sales forecasts unreliable, which matters most on newer product lines where forecast error is highest.